I.These days there is a lack of paracetamol in this country. A common remedy for pain and fever. Generally, a pharmacy has this medicine at hand as a supermarket has sugar cubes. However, many customers buy the product in larger quantities – believing that they need a fever-lowering medication at home because of the corona crisis. Other delivery bottlenecks are also associated with the wave of infections around the world. In pharmacies, for example, thyroid patients learn that certain dosages are difficult to obtain. Background: India, for example, has blocked two dozen active substances for export. As a result, funds intended for Europe are scarce there. That plays Jacques Brom into the cards. Because the manager of the pharmaceutical company Sanofi also advertises an ambitious project in Frankfurt. Sanofi operates its largest plant in Höchst.
The company plans to bundle six of its eleven active ingredient factories into one new company and to launch the unit in 2022. The stated goal: The company should secure the supply of active ingredients in Europe and help alleviate the currently widely voiced dependence on manufacturers in Asia. For example, the Flörsheim-based pharmaceutical manufacturer Hennig reported on delivery bottlenecks for seven active ingredients produced in India.
All six Sanofi factories in question are located in Europe, two of them in France, one each in Frankfurt, Hungary, Italy and the United Kingdom. The largest location is in France, as Brom said, the second largest on the Main. Sanofi produces active ingredients developed by Hoechst AG in the Höchst plant, such as the cardiovascular agent Ramipril or the antiallergic agent fexofenadine. Among other things, the company wants to integrate the factories responsible for these active ingredients into the unit to be formed.